Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1
de Spéville, B. D. Felip, E. Forster, M. Majem, M. Bajaj, P. Peguero, J. A. Carcereny, E. Krebs, Matthew G Mukherjee, U. Mueller, C.
de Spéville, B. D.
Felip, E.
Forster, M.
Majem, M.
Bajaj, P.
Peguero, J. A.
Carcereny, E.
Krebs, Matthew G
Mukherjee, U.
Mueller, C.
Citations
Altmetric:
Abstract
Description
Date
2023
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
de Spéville BD, Felip E, Forster M, Majem M, Bajaj P, Peguero JA, et al. Final results from TACTI-002 Part C: A phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with metastatic 2nd line head and neck squamous cell carcinoma unselected for PD-L1. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003150.